9
total announcements
ALPA.NS · 15 min delayed
Alpa Laboratories Limited
Alpa Laboratories Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a net profit of Rs. 103.84 crores and a basic and diluted EPS of Rs. 0.52.
Alpa Laboratories Limited
Alpa Laboratories Limited has informed the Exchange regarding a clarification on the board meeting date, correcting a typographical error that mentioned the meeting as scheduled for August 14, 2026, instead of August 13, 2026.
Alpa Laboratories Limited
Alpa Laboratories Limited has informed the Exchange about General Updates, including approval in principle for exploring the proposed promotion and incorporation of an overseas company in Nigeria, Alpa Biopharm Limited, in association with Blueseal Pharmaceuticals Limited, Nigeria.
Alpa Laboratories Limited
Alpa Laboratories Limited has responded to a clarification request from the Exchange regarding its financial results for the quarter ended 31-Mar-2026, as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Alpa Laboratories Limited
Alpa Laboratories Limited has informed the Exchange regarding the cessation of Ms. Jyoti Jain as a Non-Executive Independent Director of the company, effective July 21, 2026, due to the completion of her tenure.
Alpa Laboratories Limited
Alpa Laboratories Limited has informed the Exchange regarding Cessation of Ms Yashoda Patidar as Company Secretary & Compliance Officer of the company w.e.f. July 26, 2026.
Alpa Laboratories Limited
Alpa Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in securities/shares of the company shall remain closed from 1st July, 2026 till 48 hours after the declaration of the Financial Results by the Company for the First Quarter ending June 30, 2026.
Alpa Laboratories Limited
NSE-listed Alpa Laboratories Limited has been sought clarification by the exchange for the quarter ended 31-Mar-2026 regarding Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company is required to clarify certain information, but its response is awaited.
Alpa Laboratories Limited
Alpa Laboratories Limited has submitted a disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 to the exchange. This regulation mandates promoters to disclose details of any shares they have encumbered in the company. The submission signifies compliance with regulatory obligations. While this announcement doesn't detail the specifics, such filings are important for investors as they provide transparency on potential changes in promoter shareholdings or pledges, which can influence market perception.